{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:13:13Z","timestamp":1789668793951,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["25 4355Pj"],"award-info":[{"award-number":["25 4355Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-1010463"],"award-info":[{"award-number":["R-1010463"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-02445"],"award-info":[{"award-number":["2020-02445"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["UMTP2023-MF02"],"award-info":[{"award-number":["UMTP2023-MF02"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152997","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:06:23Z","timestamp":1778367983000},"page":"152997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of second primary cancer and death in patients with idiopathic inflammatory myopathies"],"prefix":"10.1016","volume":"78","author":[{"given":"Weng Ian","family":"Che","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Baecklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-5260","authenticated-orcid":false,"given":"Marie","family":"Holmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152997_bib0001","series-title":"Managing Myositis: A Practical Guide","first-page":"237","article-title":"Cancer-Associated Myositis","author":"Selva-O\u2019Callaghan","year":"2020"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2020.12.009","article-title":"Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016","volume":"51","author":"Dani","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152997_bib0004","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152997_bib0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152997_bib0007","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2009.09274.x","article-title":"Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study","volume":"161","author":"Huang","year":"2009","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152997_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152997_bib0009","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-gamma antibody in patients with dermatomyositis","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152997_bib0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/joim.20003","article-title":"Impact of cancer on the mortality of patients with idiopathic inflammatory myopathies by flexible parametric multistate modelling","volume":"296","author":"Che","year":"2024","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-022-02963-y","article-title":"Long-term secular trends in dermatomyositis and polymyositis mortality in the USA from 1981 to 2020 according to underlying and multiple cause of death mortality data","volume":"25","author":"Qiao","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152997_bib0012","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1093\/rheumatology\/keaa661","article-title":"Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study","volume":"60","author":"D'Silva","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152997_bib0013","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.semarthrit.2020.08.009","article-title":"Mortality trends in polymyositis and dermatomyositis: a general population-based study","volume":"50","author":"Li","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152997_bib0014","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register \u2013 A sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"issue":"29","key":"10.1016\/j.semarthrit.2026.152997_bib0016","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1002\/sim.7448","article-title":"Parametric multistate survival models: flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences","volume":"36","author":"Crowther","year":"2017","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152997_bib0017","first-page":"2014","article-title":"A package for survival analysis in R","volume":"2","author":"Therneau","year":"2015","journal-title":"R pack ver"},{"key":"10.1016\/j.semarthrit.2026.152997_bib0018","series-title":"A Language and Environment for Statistical Computing","year":"2025"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","article-title":"Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study","volume":"25","author":"Kjaer","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152997_bib0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152997_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152997_bib0022","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152997_bib0023","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:57:49Z","timestamp":1789667869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S0049017226000867"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152997","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of second primary cancer and death in patients with idiopathic inflammatory myopathies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152997"}}